Brought to you by 
Critical Therapeutics, SkyePharma develop asthma & COPD drug
22 Jul 2004
Executive Summary
Following Abbott Laboratories' decision to discontinue production of its asthma drug Zyflo, SkyePharma PLC and critical care medicine company Critical Therapeutics Inc. have picked up the generic--zileuton--and will develop a controlled-release formulation to treat asthma as well as chronic obstructive pulmonary disease (COPD).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Critical Therapeutics, SkyePharma develop asthma & COPD drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice